3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Phase 2
2
Phase NA
1
Phase EARLY_PHASE1
1
Status
Withdrawn
1
Recruiting
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Genitourinary
3
Breast
3
Lymphoid
2
Gynecologic
2
Other hematologic neoplasm
1
Myeloid
1
Gastrointestinal
1
CNS
1
Conditions
Ovarian Neoplasms
2
Breast Neoplasms
2
Triple Negative Breast Neoplasms
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Neoplasms
1
Neoplasm Metastasis
1
Kidney Neoplasms
1
Colonic Neoplasms
1
Carcinoma, Renal Cell
1
Brain Neoplasms
1
Interventions
Paclitaxel
150
Carboplatin
110
Cisplatin
95
Bevacizumab
42
Topotecan
39
Gemcitabine
38
liposomal doxorubicin
34
Radiotherapy
29
Doxorubicin
27
Brachytherapy
26
Taxes
24
pembrolizumab
20
olaparib
20
Drug Therapy
20
Hyperthermic Intraperitoneal Chemotherapy
16
Chemotherapy, Adjuvant
16
human papillomavirus vaccine, L1 type 16, 18
15
Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18
14
Docetaxel
13
Neoadjuvant Therapy
12
Platinum
10
niraparib
9
Radiation
9
1,2-diaminocyclohexaneplatinum II citrate
9
Vaccines, Synthetic
8
Surgical Procedures, Operative
8
atezolizumab
7
Specimen Handling
7
Papillomavirus Vaccines
7
Letrozole
7
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 3
×
Atorvastatin
×
Gynecologic
×
Clear all
NCT05796973
2025-06-27
MOVES
Tampere University Hospital
Phase 3
Recruiting
240 enrolled
NCT02201381
2022-07-18
METRICS
Health Clinics Limited
Phase 3
Withdrawn